Neoplasms – Talk Bio

Kymera Faces Sanofi Setback but Secures $750M Gilead Oncology Deal

1 week ago talkbio0Tagged CDK2 protein, human, Gilead, Kymera, Molecular Glue Degrader, Neoplasms, protein degrader, sanofi

Kymera; Sanofi; Gilead; molecular glue degrader; CDK2; oncology; deal; protein degrader

Nuvalent Reports Positive Pivotal Data for ROS1-Targeted Lung Cancer Drug; Rolling FDA Submission Planned

1 week ago talkbio0Tagged ARROS-1 trial, Frequency of Responses, Metastatic malignant neoplasm to brain, Neoplasms, Non-Small Cell Lung Carcinoma, Nuvalent, Protein-tyrosine kinase inhibitor, ROS1-positive Lung Cancer, Submission, United States Food and Drug Administration, zidesamtinib

Nuvalent; ROS1-positive lung cancer; zidesamtinib; FDA submission; ARROS-1 trial; NSCLC; tyrosine kinase inhibitor; objective response rate; brain metastases; oncology

Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development

2 weeks ago talkbio0Tagged Clinical Development, daraxonrasib, Neoplasms, Pharma, RAS, RAS cancer, Revolution Medicines, Royalty, secured debt, synthetic royalty

Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine

BioNTech to Acquire CureVac in $1.25B All-Stock mRNA Deal

3 weeks ago talkbio0Tagged Acquisition, all-stock, BioNTech, Biotechnology, Cancer Therapeutic Procedure, COVID-19 Vaccines, CureVac, Germany, mRNA Vaccines, Neoplasms

BioNTech; CureVac; acquisition; mRNA vaccines; cancer treatment; all-stock deal; Germany; biotechnology; oncology; COVID-19 vaccine

Antares Therapeutics Launches with $177M to Tackle ‘Undruggable’ Targets After Scorpion Spinout

3 weeks ago talkbio0Tagged Antares, biotech spinoff, Eli Lilly acquisition, Neoplasms, Precision Medicine, preclinical pipeline, Scorpions, targets

Antares Therapeutics; Scorpion Therapeutics; biotech spinoff; $177M Series A; undruggable targets; oncology; precision medicine; Eli Lilly acquisition; preclinical pipeline